Holst JJ - Search Results

1

Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study.

Laakso M, Zilinskaite J, Hansen T, Boesgaard TW, Vänttinen M, Stancáková A, Jansson PA, Pellmé F, Holst JJ, Kuulasmaa T, Hribal ML, Sesti G, Stefan N, Fritsche A, Häring H, Pedersen O, Smith U; EUGENE2 Consortium. Laakso M, et al. Among authors: holst jj. Diabetologia. 2008 Mar;51(3):502-11. doi: 10.1007/s00125-007-0899-2. Epub 2007 Dec 14. Diabetologia. 2008. PMID: 18080106

2

The effect of intraportal and peripheral infusions of glucagon on insulin and glucose concentrations and glucose tolerance in normal man.

Holst JJ, Madsen OG, Knop J, Schmidt A. Holst JJ, et al. Diabetologia. 1977 Sep;13(5):487-90. doi: 10.1007/BF01234501. Diabetologia. 1977. PMID: 908472

3

Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity.

Holst JJ, Schwartz TW, Lovgreen NA, Pedersen O, Beck-Nielsen H. Holst JJ, et al. Int J Obes. 1983;7(6):529-38. Int J Obes. 1983. PMID: 6360922

4

Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships.

Ritzel R, Orskov C, Holst JJ, Nauck MA. Ritzel R, et al. Among authors: holst jj. Diabetologia. 1995 Jun;38(6):720-5. doi: 10.1007/BF00401846. Diabetologia. 1995. PMID: 7672496 Clinical Trial.

5

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Nauck MA, et al. Among authors: holst jj. Diabetologia. 1993 Aug;36(8):741-4. doi: 10.1007/BF00401145. Diabetologia. 1993. PMID: 8405741 Clinical Trial.

6

Impaired insulin-stimulated nonoxidative glucose metabolism in pancreas-kidney transplant recipients. Dose-response effects of insulin on glucose turnover.

Christiansen E, Vestergaard H, Tibell A, Hother-Nielsen O, Holst JJ, Pedersen O, Madsbad S. Christiansen E, et al. Among authors: holst jj. Diabetes. 1996 Sep;45(9):1267-75. doi: 10.2337/diab.45.9.1267. Diabetes. 1996. PMID: 8772733

7

GLP-1 does not not acutely affect insulin sensitivity in healthy man.

Orskov L, Holst JJ, Møller J, Orskov C, Møller N, Alberti KG, Schmitz O. Orskov L, et al. Among authors: holst jj. Diabetologia. 1996 Oct;39(10):1227-32. doi: 10.1007/BF02658511. Diabetologia. 1996. PMID: 8897012 Clinical Trial.

8

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B. Nauck MA, et al. Among authors: holst jj. Diabetologia. 1996 Dec;39(12):1546-53. doi: 10.1007/s001250050613. Diabetologia. 1996. PMID: 8960841 Clinical Trial.

9

Novel MODY3 mutations in the hepatocyte nuclear factor-1alpha gene: evidence for a hyperexcitability of pancreatic beta-cells to intravenous secretagogues in a glucose-tolerant carrier of a P447L mutation.

Hansen T, Eiberg H, Rouard M, Vaxillaire M, Møller AM, Rasmussen SK, Fridberg M, Urhammer SA, Holst JJ, Almind K, Echwald SM, Hansen L, Bell GI, Pedersen O. Hansen T, et al. Among authors: holst jj. Diabetes. 1997 Apr;46(4):726-30. doi: 10.2337/diab.46.4.726. Diabetes. 1997. PMID: 9075819

10

Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia.

Toft-Nielsen M, Madsbad S, Holst JJ. Toft-Nielsen M, et al. Among authors: holst jj. Diabetologia. 1998 Oct;41(10):1180-6. doi: 10.1007/s001250051049. Diabetologia. 1998. PMID: 9794105

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,781 results

Search Page

Filters